



Health, Healthy Living and Seniors

Public Health and Primary Health Care Division

Communicable Disease Control

4th Floor, 300 Carlton St. Winnipeg, MB R3B 3M9

T 204-788-6737 F 204-948-2040

www.manitoba.ca

November 30, 2015

Dear Health Care Provider:

Updated: Pneumococcal Polysaccharide (Pneu-P-23) Vaccine Eligibility Criteria

Manitoba Health, Healthy Living and Seniors (MHLS) eligibility criteria for publicly-funded (i.e. free-of-charge) pneumococcal polysaccharide (Pneu-P-23) vaccine is as follows:

- All individuals ≥ 65 years of age are eligible to receive 1 dose.
- All residents of a personal care home or a long-term care facility are eligible to receive 1 dose.
- Individuals from 2 to 65 years of age with the following high-risk medical conditions are eligible to receive 1 dose:
 - Chronic cerebral spinal fluid (CSF) leak
 - Cochlear implants (including those children who are to receive implants)
 - Chronic cardiac or pulmonary disease
 - Diabetes mellitus
 - Chronic kidney disease
 - Chronic liver disease (including hepatic cirrhosis due to any cause)
 - Sickle cell disease or other hemoglobinopathies
 - Congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions
 - Asplenia (functional or anatomic)
 - Immunocompromising therapy including use of long-term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, and certain anti-rheumatic drugs
 - HIV infection
 - Hematopoietic stem cell transplant (recipient)
 - Solid organ or islet transplant (candidate or recipient)
 - Chronic neurologic condition that may impair clearance of oral secretions
 - Malignant neoplasms including leukemia and lymphoma
 - Nephrotic syndrome
- All individuals who are homeless are eligible to receive 1 dose.
- Individuals who are illicit drug users are eligible to receive 1 dose.

- One lifetime re-immunization after 5 years is recommended for the following individuals at highest risk for invasive pneumococcal disease (IPD):
 - Asplenia (functional or anatomic)
 - Sickle cell disease
 - Hepatic cirrhosis
 - Chronic renal failure
 - Nephrotic syndrome
 - HIV infection
 - Immunosuppression related to disease or therapy †

† For a list of patients eligible under this category, see the Canadian Immunization Guide at: www.phac-aspc.gc.ca/publicat/ciq-gci/p03-07-eng.php.

Adults that have a prescription for pneumococcal conjugate (Pneu-C-13) vaccine will need to pay out of pocket for the purchase and administration, unless they are hematopoietic stem cell transplant (HSCT) recipients, living with human immunodeficiency virus (HIV) and/or solid organ transplant recipients (as these three high-risk patient groups can receive the vaccine free-of-charge).

For more information related to minimum intervals and dosing schedules of either Pneu-P-23 and/or or Pneu-C-13 vaccines, please visit: www.phac-aspc.gc.ca/publicat/ciq-gci/p04-pneu-eng.php.

For provincial information, please visit *Manitoba's Immunization Program Manual* at: www.gov.mb.ca/health/publichealth/cdc/div/manual/index.html.

MHLS provides health information resources (e.g. factsheets, posters) free-of-charge to all health care providers; go to www.gov.mb.ca/health/jmc/index.html for more information.

Sincerely,



Richard Baydack, PhD
Director, Communicable Disease Control



Tim Hilderman, MD FRCPC
Medical Lead, Communicable Disease Control